Once-Daily Fluticasone Furoate May Be Effective for Persistent Asthma
the MPR take:
A new study published in the journal Respiratory Research evaluates the use of a once-daily dosing regimen for the inhaled corticosteroid (ICS) fluticasone furoate vs. placebo in patients with asthma uncontrolled by non-inhaled corticosteroids. Previous literature has shown that adherence to asthma management therapy is better with a once-a-day regimen vs. twice-a-day dosing. In this study, treatment with fluticasone furoate 50mcg once-daily significantly improved evening trough FEV1. For all efficacy endpoints, greater improvements were seen with fluticasone furoate 50mcg/day vs. placebo. Also, compared to placebo, fluticasone furoate improved the percentage of rescue-free 24-hour periods. Researchers conclude that a once-daily regimen of fluticasone furoate 50mcg may be an effective treatment option for patients ≥12 years old with persistent asthma that cannot be controlled by non-ICS therapy.
Background: Fluticasone furoate (FF) is a novel, once-daily inhaled corticosteroid (ICS) that has been shown to improve lung function vs. placebo in asthma patients. This study evaluated the efficacy and safety of FF 50mcg compared with placebo in asthma patients uncontrolled by non-ICS therapy. Methods: This 12-week, multicentre, randomized, double-blind, placebo-controlled, parallel-group, phase III study randomized 248 patients (aged ≥12 years) to once-daily FF 50mcg administered via the ELLIPTA dry powder inhaler or placebo.